Remegen (Yantai) Pharmaceutical Co., Ltd. ("Remegen") announced its 2024 interim report, showing revenue of RMB 739,656 thousand for the period, an increase compared to the same period last year. However, the company recorded a loss of RMB 780,460 thousand during the same period, with a gross profit of RMB 570,385 thousand. During the reporting period, Remegen continued to focus on biomedical research, biomedical services, and biomedical production and sales. The company has business income in both the China mainland and USA markets, with China mainland being the primary market. As of June 30, 2024, Remegen's non-current assets totaled RMB 3,260,658 thousand, while current assets totaled RMB 2,493,879 thousand. The ending cash and cash equivalents amounted to RMB 673,322 thousand. The company did not declare or distribute any interim dividends.

Remegen (Yantai) Pharmaceutical Co., Ltd. ("Remegen") announced its 2024 interim report, showing revenue of RMB 739,656 thousand for the period, an increase compared to the same period last year. However, the company recorded a loss of RMB 780,460 thousand during the same period, with a gross profit of RMB 570,385 thousand. During the reporting period, Remegen continued to focus on biomedical research, biomedical services, and biomedical production and sales. The company has business income in both the China mainland and USA markets, with China mainland being the primary market. As of June 30, 2024, Remegen's non-current assets totaled RMB 3,260,658 thousand, while current assets totaled RMB 2,493,879 thousand. The ending cash and cash equivalents amounted to RMB 673,322 thousand. The company did not declare or distribute any interim dividends.